RESORB Bioresorbable Drug Eluting Vascular Scaffold.

Intended Use:

RESORB Bioresorbable Drug Eluting Vascular Scaffold is intended for improving coronary luminal diameter in patients with symptomatic ischemic heart disease in de novo coronary artery lesion in native coronary arteries with a reference vessel diameter of 2.25 mm to 4.50 mm and a lesion length ≤40 mm.
Resorb is intended for use in patients eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA).
Resorb consist of proprietary formulation of PLLA polymer. The formulation is so designed to provide excellent radial strength, minimum recoil, uniform expansion, prefect arterial support & optimum dissolution properties.
Resorb is coated with Sirolimus Drug and polymer formulation. This drug selectively stop cell growth, by blocking cell-cycle progression and eventually inhibit Cell Proliferation and Restenosis.
Drug coated bioresorbable stent is crimped onto the PTCA Balloon Delivery catheter. It provide the means for carrying the stent through the coronary vasculature and for proper positioning of the stent within the vasculature.
Resorb Radial Strength.
Radial Strength of Resorb is superior than that of Absorb Bioresorbable Vascular Scaffold (BVS). Hence proposing a good clinical outcome.
Sources: Resorb & Flexia Data on file at Nano Therapeutics Pvt Ltd.
Published Data: Resorb & Xience data: Abbort Vascular Data Presentation - ABSORB Bioresorbable Vascular Scaffold System - The 4th Revolution in Interventional Cardiology, 17th Asian Harmonization Working Party Annual Conference, 2-6 Nov 2012, Taipei
Mechanism of Invitro Degradation
Polymer Hydration:
PLLA polymers are hydrophilic; Polymer undergoes hydration when they come in contact with water based solution into the dissolution apparatus.
Water penetrates inside the amorphous region of the polymer which results into reduction of molecular weight.
Polymer fragmentation:
Formation into low weight polymer segments due to scission of the amorphous tied chains linking the crystalline regions leads to reduction of radial strength of polymeric device.
RESORB Stent Shows Excellent Engineering Performance.

Histopathology Study in Porcine Model

Representative Photomicrographs at 1 month follow up
Resorb Stents were well expanded and lumens were patent with no vessel occlusion for
all animals reaching the predefined time-point of 1 month.
Representative Angiographic Images of Implanted Coronary Arteries of Porcine Model
Immediate Post Procedure angiographic image
28 days Post Procedure angiographic image
~ Results shows the vassel is patent at 28 days Post Procedure in porcine model
“Not Available for Sale”
Resorb is registered trade mark of Nano Therapeutics Pvt. Ltd.
All rights reserved by Nano Therapeutics Pvt Ltd @ 2014